Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(VQAYFKKCNSOZKM-IOSLPCCCSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/247943CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF
WO 01.12.2022
Int.Class C12N 15/67
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
67General methods for enhancing the expression
Appl.No PCT/CN2022/095749 Applicant SHANGHAI CIRCODE BIOMED CO., LTD. Inventor YANG, Yun
The present invention relates to a construct and method for preparing a circular RNA, and the use of the circular RNA. In particular, the present invention relates to a construct and method for preparing a circular RNA on the basis of a group II intron, and the use of the circular RNA.
2.WO/2022/251484TREATMENT OF COMPLEMENT-MEDIATED DISORDERS
WO 01.12.2022
Int.Class A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
Appl.No PCT/US2022/031115 Applicant APELLIS PHARMACEUTICALS, INC. Inventor SCHEIBLER, Lukas
Inappropriate or excessive complement activation is an underlying cause or contributing factor to a number of serious diseases and conditions, and considerable effort has been devoted over the past several decades to exploring various complement inhibitors as therapeutic agents. RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.
3.WO/2022/250072THERAPEUTIC AGENT FOR CARDIAC DISEASE
WO 01.12.2022
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
Appl.No PCT/JP2022/021330 Applicant LUXNA BIOTECH CO., LTD. Inventor MIYASAKA, Yui
The present invention provides a therapeutic agent for cardiac disease that includes an oligonucleotide having one or more nucleotides represented by formula I or formula II below: (in formulas I and II: Base represents a 2-oxo-1, 2-dihydropyrimidine-1-yl group or purine-9-yl group that may have one or more arbitrary substituents selected from an α group; the α group comprises hydroxyl groups, hydroxyl groups protected by a nucleic-acid-synthesis protective group, C1 to C6 straight-chain alkyl groups, C1 to C6 straight-chain alkoxy groups, mercapto groups, mercapto groups protected by a nucleic-acid-synthesis protective group, C1 to C6 straight-chain alkylthio groups, amino groups, C1 to C6 straight-chain alkylamino groups, amino groups protected by a nucleic-acid-synthesis protective group, and halogen atoms; R1, R12, and R13 each independently represent a hydrogen atom, a C1 to C7 alkyl group that may form a branch or ring, or a protective group for an amino group; and R14 represents a hydrogen atom).
4.WO/2022/248353ADJUVANTS
WO 01.12.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2022/063709 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor HANON, Emmanuel Jules
The present invention relates to immunisation using carrier-formulated mRNA in conjunction with an adjuvant comprising a STING agonist, and to related aspects.
5.WO/2022/248572CIRCRNAS FOR GENE SILENCING
WO 01.12.2022
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
Appl.No PCT/EP2022/064246 Applicant MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Inventor KRAGLER, Friedrich
The present invention relates to the field of gene silencing. The present invention inter alia concerns circular RNAs, compositions and kits comprising circular RNAs, methods of producing circular RNAs, methods of inhibiting the expression of a target gene or the function of a target gene in a cell, and uses of circular RNAs and compositions comprising circular RNAs.
6.WO/2022/251644NR4A3-DEFICIENT IMMUNE CELLS AND USES THEREOF
WO 01.12.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/US2022/031356 Applicant LYELL IMMUNOPHARMA, INC. Inventor LAM, Viola
The preset disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to express reduced levels of NR4A3 gene and/or NR4A3 protein. Also provided are modified cells, e.g., immune cell, which have been modified to express reduced levels of NR4A3 gene and/or NR4A3 protein. Reducing levels of NR4A3 gene and/or NR4A3 protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
7.WO/2022/248566METHODS FOR STORING MRNA COMPOSITIONS
WO 01.12.2022
Int.Class A01N 1/00
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
1Preservation of bodies of humans or animals, or parts thereof
Appl.No PCT/EP2022/064237 Applicant ETHERNA IMMUNOTHERAPIES NV Inventor CHALLIS, Phillip
The present invention relates to the field of RNA-containing compositions, more in particular in the stabilization of in vitro transcribed mRNA-containing compositions for frozen storage. Specifically, the present invention provides a solution for reducing or avoiding the formation of aggregates/precipitates in such RNA-containing compositions, even when being frozen and subsequently thawed. Thereto, the present invention provides means and methods for preventing the formation of aggregates/precipitates in a frozen or thawed RNA-containing composition, by adding a metal binding chelator to said composition prior to freezing said composition.
8.WO/2022/243484NANOPARTICLE DELIVERY SYSTEM FOR PRODUCTION OF ENGINEERED EXTRACELLULAR VESICLES
WO 24.11.2022
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No PCT/EP2022/063655 Applicant EVOX THERAPEUTICS LIMITED Inventor GUPTA, Dhanu
The present invention relates to engineered extracellular vesicles (EVs) as a therapeutic modality for the treatment of various severe diseases. More specifically, the invention relates to delivery of nucleic acid cargos by a peptide delivery vector which enables a novel approach to manufacturing engineered EVs which extends their half-life and alters their biodistribution, resulting in a novel therapeutic modality able to carry various types of drugs suitable for application in not only genetic diseases but more broadly across essentially all therapeutic areas.
9.WO/2022/242660SYSTEM AND METHODS FOR INSERTION AND EDITING OF LARGE NUCLEIC ACID FRAGMENTS
WO 24.11.2022
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No PCT/CN2022/093401 Applicant WUHAN UNIVERSITY Inventor YIN, Hao
Provided are compositions and methods useful for inserting a larger nucleic acid fragment to a target genome sequence. The editing system employs a pair of pegRNA which, by virtue of their targeting nearby genomic sites and having sequences complementary to each other, collectively form a template for inserting a large exogenous sequence to the target genomic locus.
10.20220370489Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors
US 24.11.2022
Int.Class A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
Appl.No 17678792 Applicant Regeneron Pharmaceuticals, Inc. Inventor Gaurang Patel

The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.